Press Releases Archives Public Relations Contacts	Font Size:   May 8, 2008   U.S. Food and Drug Administration Approves ABILIFYŽ (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features   May 6, 2008   American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health - Supported by a Grant from Otsuka America Pharmaceutical, Inc.   April 1, 2008   American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants - Supported by a Grant from Otsuka America Pharmaceutical, Inc.   February 29, 2008   U.S. Food and Drug Administration Approves ABILIFYŽ (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)   November 20, 2007   U.S. Food and Drug Administration Approves ABILIFYŽ (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)   November 15, 2007   ABILIFYŽ (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration   November 6, 2007   U.S. Food and Drug Administration Approves ABILIFYŽ (aripiprazole) for Adolescent Patients with Schizophrenia   October 2, 2007   Meretek Diagnostics, Inc. and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger   August 14, 2007   American Psychiatric Foundation Announces Recipients of 2007 Awards for Advancing Minority Mental Health
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989